12 completed, 6 recruiting, 6 terminated, 2 unknown. 29 Phase 2, 5 Phase 1, 5 Phase 3.
Follow Famotidine: new trials by email Literature Review of Famotidine trials Research Report on Famotidine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dexamethasone De-Escalation in Neoadjuvant Chemoimmunotherapy for Triple-Negative Breast Cancer Dexamethasone, Famotidine, Diphenhydramine - Triple Negative Breast Cancer, Triple Negative Breast Cancer (TNBC) | Phase 2 | Not yet recruiting | Washington University School of Medicine | 17 | 2026-11-30 | 2026-11-03 |
| A Study to Prevent Infantile Spasms Relapse Prednisolone, Famotidine, Placebo - Infantile Spasms, Infantile Epileptic Spasms Syndrome | Phase 2 | Recruiting | University of California, Los Angeles | 40 | 2025-05-05 | 2025-05-08 |
| Post-Cardiac Surgery Acute Kidney Injury Prevention by Administration of Proton Pump Inhibitor (P2 Trial) Protonix (Pantoprazole) 40 mg q 12 hrs for 3 days, Pepcid (Famotidine) 20 mg q 12 hrs for 3 days - Acute Kidney Injury | Phase 2 | Recruiting | The University of Texas Health Science Center, Houston | 400 | 2025-01-24 | 2025-05-14 |
| Exploring Novel Therapeutic Approaches for Disorders of Gut-Liver-Brain Interaction-H1/H2 Famotidine, Levocetirizine, Fuyuan Gasmin - Functional Gastrointestinal Disorders | Phase 2 | Recruiting | Buddhist Tzu Chi General Hospital | 45 | 2025-01-01 | 2026-10-05 |
| A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease BMS-986470, Placebo, Famotidine - Anemia, Sickle Cell, Healthy Volunteers | Phase 1 / Phase 2 | Recruiting | Bristol-Myers Squibb | 224 | 2024-07-17 | 2026-08-18 |
| Novel Preventive Approach Against Filgrastim-Induced Bone Pain in Cancer Patients Placebo, famotidine and loratadine - Breast Cancer, Filgrastim Adverse Reaction | Phase 1 / Phase 2 | Completed | Noha Mansour | 58 | 2024-02-01 | 2024-12-13 |
| A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma Dexamethasone, Diphenhydramine, Famotidine - Metastatic Appendiceal Adenocarcinoma, Intraperitoneal Paclitaxel | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 39 | 2024-01-30 | 2026-07-16 |
| Prevention of Post-Cardiac Surgery Acute Kidney Injury by Proton Pump Inhibitor Pantoprazole, Famotidine - Acute Kidney Injury | Phase 2 | Completed | The University of Texas Health Science Center, Houston | 100 | 2024-01-10 | 2026-03-10 |
| A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology Paclitaxel, Dexamethasone, Diphenhydramine - Gastric Adenocarcinoma, Carcinomatosis | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2023-09-08 | 2026-05-22 |
| Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) in Hospitalized Patients With COVID-19 (Addendum 1) Famotidine, Celecoxib, Placebo - 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection | Phase 2 | Withdrawn | Leidos Life Sciences | 2023-02-07 | 2023-10-10 | |
| Interest of Famotidine in Children With Sickle Cell Disease Famotidine 400 mg/50 mL - Sickle Cell Disease | Phase 2 / Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 30 | 2022-01-12 | 2025-10-08 |
| Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients Famotidine, Celecoxib, Placebo - 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection | Phase 2 | Terminated | Leidos Life Sciences | 4 | 2021-12-29 | 2024-07-09 |
| LEAP-CT for Treatment of COVID-19 Patients (Master Protocol) Famotidine, Celecoxib, Placebo - 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection | Phase 2 | Completed | Leidos Life Sciences | 4 | 2021-12-29 | 2025-12-16 |
| Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III) UX053, Placebo, Antipyretic - Glycogen Storage Disease Type III | Phase 1 / Phase 2 | Terminated | Ultragenyx Pharmaceutical Inc | 9 | 2021-10-18 | 2024-04-16 |
| Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD) elotuzumab, placebo for elotuzumab, methylprednisolone - IgG4 Related Disease, IgG4-RD | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 8 | 2021-10-13 | 2026-02-05 |
| Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel Cimetidine, Dexamethasone, Diphenhydramine - Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8 | Phase 2 / Phase 3 | Completed | Ohio State University Comprehensive Cancer Center | 130 | 2021-10-07 | 2025-08-20 |
| Combined Antihistaminics Therapy in COVID 19 Patients Loratadine, Famotidine - Covid19 | Phase 2 / Phase 3 | Completed | Ain Shams University | 214 | 2021-09-13 | 2023-08-25 |
| Famotidine vs Placebo for the Treatment of Non-Hospitalized Adults With COVID-19 Famotidine, Placebo - Covid-19 | Phase 2 | Completed | Northwell Health | 56 | 2021-01-19 | 2026-06-15 |
| Initiation of Acid Suppression Therapy Prospective Outcomes for Laryngomalacia Famotidine, Speech Language Therapy - Laryngomalacia, Gastro Esophageal Reflux | Phase 1 / Phase 2 | Terminated | Reema Padia | 65 | 2020-11-18 | 2025-07-20 |
| An Outpatient Study Investigating Non-prescription Treatments for COVID-19 chlorine dioxide, zinc acetate, Famotidine - COVID-19 | Phase 2 | Terminated | Profact, Inc. | 10 | 2020-11-15 | 2022-09-30 |
Showing 20 of 29. Sign in to see all of them.
COVID-19 (7) · Breast Neoplasms (3) · Acute Kidney Injury (2) · Anemia, Sickle Cell (2) · Gastroesophageal Reflux (2) · Gastrointestinal Diseases (2) · Adenocarcinoma, Mucinous (1) · Brain Edema (1) · Breast Carcinoma In Situ (1) · Carcinoma (1) · Communication Disorders (1) · Coronavirus Infections (1) · Disease (1) · Dyskinesias (1) · Dyspepsia (1)
Leidos Life Sciences (3) · M.D. Anderson Cancer Center (2) · The University of Texas Health Science Center, Houston (2) · Ain Shams University (1) · Assistance Publique - Hôpitaux de Paris (1) · Astellas Pharma Inc (1) · Bristol-Myers Squibb (1) · Buddhist Tzu Chi General Hospital (1) · Icahn School of Medicine at Mount Sinai (1) · Jesper Ekelund (1) · Mayo Clinic (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Noha Mansour (1) · Northwell Health (1) · Ohio State University Comprehensive Cancer Center (1)
United States (21) · Canada (2) · Egypt (2) · France (2) · Italy (2) · Finland (1) · Japan (1) · Spain (1) · Sweden (1) · Taiwan (1) · United Kingdom (1)
Brian A Roberts, MS, PMP (2) · Yafen Liang, MD (2) · Beth Helmink, MD (1) · Brian Badgwell, MD (1) · Dawn Francis, MD (1) · Derek W Russell, MD (1) · Everett Vokes, MD (1) · Faisal Fa'ak, MD (1) · Jesper Ekelund, MD, PhD (1) · John H. Stone, MD, MPH (1) · Jonathan Murphy, MD, MD(H) (1) · Kathleen D Liu, MD (1) · Laura Esserman, MD (1)
PMID 34473343, PMID 36883141, PMID 37722599, PMID 38842838, PMID 39592213, PMID 39761829, PMID 40462830, PMID 40762274, PMID 42799508
2023 (1), R61HL142539 (1), UM1AI144298 (1)